Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

PRINCIPAL FINANCIAL DATA OF SINOPHARM ACCORD

FOR THE THREE MONTHS ENDED 31 MARCH 2018

Reference is made to the overseas regulatory announcement dated 23 April 2018 (the "Announcement") and issued by Sinopharm Group Co. Ltd. (the "Company") in relation to the first quarterly report for the three months ended 31 March 2018 of China National Accord Medicines Corporation Ltd. ("Sinopharm Accord"), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code: 000028 for A shares; 200028 for B shares).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of Sinopharm Accord for the three months ended 31 March 2018 as set out in the Announcement.

PRINCIPAL FINANCIAL DATA OF SINOPHARM ACCORD

Unit: Yuan Currency: RMB

Current periodSame period of last yearChanges of this period over same period of last year

Operating income

10,256,566,731.51

10,222,459,812.55

0.33%Net profit attributable to shareholders of the listed company

292,731,685.33

272,564,318.71

7.40%

Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses

284,982,162.39

271,249,398.43

5.06%Net cash flow arising from operating activities

-864,716,289.96

-502,263,276.11

-72.16%

Basic earnings per share (RMB/Share)

0.68

0.64

6.25%

Diluted earnings per share (RMB/Share)Weighted average ROE

0.68 3.07%

0.64 3.17%

6.25% -0.10%

At the end of the reporting periodAt the end of last year

Changes of this period-end over same period-end of last year

Total assets

23,760,905,981.51

22,343,643,527.77

6.34%Net assets attributable to shareholders of listed company

9,689,304,031.21

9,396,572,345.88

3.12%

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board of Sinopharm Group Co. Ltd.

Li Zhiming Chairman

Shanghai, the PRC 23 April 2018

As at the date of this announcement, the executive directors of the Company are Mr. Li Zhiming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Ma Ping, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Rong Yan and Mr. Wu Yijian; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong and Mr. Zhuo Fumin.

* The Company is registered as a non-Hong Kong company under the Hong Kong

Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".

Attachments

  • Original document
  • Permalink

Disclaimer

Sinopharm Group Co. Ltd. published this content on 23 April 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 23 April 2018 10:16:04 UTC